Drugs / AS15 ASCI
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01435356 Comparator | Aug 2011 → Apr 2017 | bladder transitional cell carcinoma | European Association of Urology Research Foundation | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AS15 ASCI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01435356 ↗ |
| Route | Intramuscular | “5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment...” NCT01435356 ↗ |